• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy J

tetano

Editor, Senior Moderator
Sci Rep


. 2022 Sep 29;12(1):16294.
doi: 10.1038/s41598-022-20747-x.
Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers


Aya Sugiyama[SUP] 1 [/SUP], Akemi Kurisu[SUP] 1 [/SUP], Shintaro Nagashima[SUP] 1 [/SUP], Kiyomi Hando[SUP] 1 [/SUP], Khilola Saipova[SUP] 1 2 [/SUP], Sayyora Akhmedova[SUP] 1 3 [/SUP], Kanon Abe[SUP] 1 [/SUP], Hirohito Imada[SUP] 1 [/SUP], Md Razeen Ashraf Hussain[SUP] 1 [/SUP], Serge Ouoba[SUP] 1 4 [/SUP], Bunthen E[SUP] 1 5 [/SUP], Ko Ko[SUP] 1 [/SUP], Tomoyuki Akita[SUP] 1 [/SUP], Shinichi Yamazaki[SUP] 6 [/SUP], Michiya Yokozaki[SUP] 6 [/SUP], Junko Tanaka[SUP] 7 [/SUP]



Affiliations
Free PMC article

Abstract

Several factors related to anti-spike(S) IgG antibody titers after mRNA COVID-19 vaccination have been elucidated, but the magnitude of the effects of each factor has not been fully understood. This cross-sectional study assessed anti-S and anti-nucleocapsid (N) antibody titers on 3744 healthy volunteers (median age, 36 years; IQR, 24-49 years; females, 59.0%) who received two doses of mRNA-1273 or BNT162b2 vaccine and completed a survey questionnaire. Multiple regression was conducted to identify factors associated with antibody titers. All but one participant tested positive for anti-S antibodies (99.97%). The following factors were independently and significantly associated with high antibody titer: < 3 months from vaccination (ratio of means 4.41); mRNA-1273 vaccine (1.90, vs BNT162b2); anti-N antibody positivity (1.62); age (10's: 1.50, 20's: 1.37, 30's: 1.26, 40's: 1.16, 50's: 1.15, vs ≧60's); female (1.07); immunosuppressive therapy (0.54); current smoking (0.85); and current drinking (0.96). The largest impact on anti-S IgG antibody titers was found in elapsed time after vaccination, followed by vaccine brand, immunosuppressants, previous SARS-CoV-2 infection (anti-N antibody positive), and age. Although the influence of adverse reactions after the vaccine, gender, smoking, and drinking was relatively small, they were independently related factors.
 
Back
Top Bottom